Media

Media

This section of the Akcea Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Akcea Therapeutics​ assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQAKCA
Beta1.44
Shares Outstanding101.6M
Average Volume (10 days)476.7K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.37)
Sales (TTM)$3.11
Book Value (MRQ)$4.71
Cash Flow (TTM)$0.96
Cash (MRQ)$3.84

Analyst Views

Current Mean RecommendationHold
Strong Buy0
 
Buy0
 
Hold3
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Kyle Jenne
Chief Commercial Officer
(720)
Sell
Sep 22, 2020
Joshua Patterson
General Counsel
(319)
Sell
Sep 22, 2020
Damien McDevitt
Director, Chief Executive Officer
(8,709)
Sell
Sep 22, 2020
Joshua Patterson
General Counsel
(263)
Sell
Jul 17, 2020
William T. Andrews
Chief Medical Officer
37,500
Acquire
Jul 9, 2020

Recent SEC Filings

Amended >= 5% Acquisition
Nov 10, 2020
15-12B
Oct 23, 2020
Insider Buy/Sell
Oct 14, 2020
Insider Buy/Sell
Oct 13, 2020
Insider Buy/Sell
Oct 13, 2020